Newswire (Published: Friday, July 14, 2017, Received: Thursday, July 6, 2017, 7:54:45 PM CDT)
Word Count: 544
Researchers at University of California Report New Data on Prostatectomy (Individual Patient-Level Meta-Analysis of the Performance of the Decipher Genomic Classifier in High-Risk Men After Prostatectomy to Predict Development of Metastatic ...)
By a News Reporter-Staff News Editor at Genomics & Genetics Weekly -- Fresh data on Surgery - Prostatectomy are presented in a new report. According to news originating from San Francisco, California, by NewsRx correspondents, research stated, "PurposeTo perform the first meta-analysis of the performance of the genomic classifier test, Decipher, in men with prostate cancer postprostatectomy.MethodsMEDLINE, EMBASE, and the Decipher genomic resource information database were searched for published reports between 2011 and 2016 of men treated by prostatectomy that assessed the benefit of the Decipher test. Multivariable Cox proportional hazards models fit to individual patient data were performed; meta-analyses were conducted by pooling the study-specific hazard ratios (HRs) using random-effects modeling."
Our news journalists obtained a quote from the research from the University of California, "Extent of heterogeneity between studies was determined with the I-2 test.ResultsFive studies (975 total patients, and 855 patients with individual patient-level data) were eligible for analysis, with a median follow-up of 8 years. Of the total cohort, 60.9%, 22.6%, and 16.5% of patients were classified by Decipher as low, intermediate, and high risk, respectively. The 10-year cumulative incidence metastases rates were 5.5%, 15.0%, and 26.7% (P < .001), respectively, for the three risk classifications. Pooling the study-specific Decipher HRs across the five studies resulted in an HR of 1.52 (95% CI, 1.39 to 1.67; I-2 = 0%) per 0.1 unit. In multivariable analysis of individual patient data, adjusting for clinicopathologic variables, Decipher remained a statistically significant predictor of metastasis (HR, 1.30; 95% CI, 1.14 to 1.47; P< .001) per 0.1 unit. The C-index for 10-year distant metastasis of the clinical model alone was 0.76; this increased to 0.81 with inclusion of Decipher.ConclusionThe genomic classifier test, Decipher, can independently improve prognostication of patients postprostatectomy, as well as within nearly all clinicopathologic, demographic, and treatment subgroups."
According to the news editors, the research concluded: "Future study of how to best incorporate genomic testing in clinical decision-making and subsequent treatment recommendations is warranted."
For more information on this research see: Individual Patient-Level Meta-Analysis of the Performance of the Decipher Genomic Classifier in High-Risk Men After Prostatectomy to Predict Development of Metastatic Disease. Journal of Clinical Oncology, 2017;35(18):1991-1998,38-41. Journal of Clinical Oncology can be contacted at: Amer Soc Clinical Oncology, 2318 Mill Road, Ste 800, Alexandria, VA 22314, USA (see also Surgery - Prostatectomy).
The news correspondents report that additional information may be obtained from F.Y. Feng, University of California, San Francisco, CA 94158, United States. Additional authors for this research include K. Yousefi, S. Deheshi, A.E. Ross, R.B. Den, E.M. Schaeffer, B.J. Trock, J.B. Zhang, A.G. Glass, A.P. Dicker, F. Abdollah, S.G. Zhao, L.L.C. Lam, M. du Plessis, V. Choeurng, Z. Haddad, C. Buerki, E. Davicioni, S. Weinmann and F.
Keywords for this news article include: San Francisco, California, United States, North and Central America, Prostatectomy, Genetics, Surgery, University of California.
Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2017, NewsRx LLC
University of California
Science and Technology
Health and Wellness
Medical Conditions and Diseases
Men's Health Issues
Medical Specialties and Practices
Treatments and Therapies